GKB Ophthalmics Limited carries a market capitalization of 304.20M, placing it among publicly traded companies globally. Its enterprise value stands at 342.41M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 304.20M |
| Enterprise Value | 342.41M |
GKB Ophthalmics Limited currently has 5.04M shares outstanding.
| Shares Outstanding | 5.04M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
GKB Ophthalmics Limited trades at a trailing price-to-earnings ratio of 21.77. The price-to-sales ratio is 0.18, and the price-to-book ratio stands at 5.26.
| PE Ratio | 21.77 |
| PS Ratio | 0.18 |
| PB Ratio | 5.26 |
| P/TBV Ratio | 0.48 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
On an enterprise value basis, GKB Ophthalmics Limited trades at an EV/EBITDA multiple of 6.73 and an EV/FCF ratio of 13.13. The EV/Sales ratio of 0.23 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 6.73 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.23 |
| EV / EBITDA | 6.73 |
| EV / EBIT | 6.73 |
| EV / FCF | 13.13 |
GKB Ophthalmics Limited maintains a current ratio of 1.52, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 21.23, indicating elevated leverage, while an interest coverage ratio of 1.90 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.52 |
| Quick Ratio | 0.08 |
| Debt / Equity | 21.23 |
| Debt / EBITDA | 2.29 |
| Interest Coverage | 1.90 |
GKB Ophthalmics Limited posts a return on equity of 7.48 and a return on invested capital of 7.47.
| Return on Equity (ROE) | 7.48 |
| Return on Assets (ROA) | 0.95 |
| Return on Invested Capital (ROIC) | 7.47 |
| Return on Capital Employed (ROCE) | 6.19 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.01 |
Over the trailing twelve months, GKB Ophthalmics Limited has paid 766,000.00 in income taxes, reflecting an effective tax rate of 2.47.
| Income Tax | 766,000.00 |
| Effective Tax Rate | 2.47 |
GKB Ophthalmics Limited's stock has declined approximately -19.45816% over the past 52 weeks. The 50-day moving average sits at 64.53, while the 200-day moving average is 60.74.
| Beta (5Y) | N/A |
| 52-Week Price Change | -19.45816% |
| 50-Day Moving Average | 64.53 |
| 200-Day Moving Average | 60.74 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, GKB Ophthalmics Limited generated 1.49B in revenue and converted that into 12.19M in net income, yielding earnings per share of 5.99. EBITDA reached 50.86M, while operating income came in at 50.86M.
| Revenue | 1.49B |
| Gross Profit | 436.67M |
| Operating Income | 50.86M |
| Pretax Income | 31.04M |
| Net Income | 12.19M |
| EBITDA | 50.86M |
| EBIT | 50.86M |
| Earnings Per Share (EPS) | 5.99 |
GKB Ophthalmics Limited holds 59.98M in cash and equivalents against 116.55M in total debt, resulting in a net debt position of 89.88M. Total book value stands at 50.41M, with working capital of 367.73M providing operational flexibility.
| Cash & Cash Equivalents | 59.98M |
| Total Debt | 116.55M |
| Net Debt | 89.88M |
| Equity (Book Value) | 50.41M |
| Book Value Per Share | 9.98 |
| Working Capital | 367.73M |
GKB Ophthalmics Limited operates with a gross margin of 29.29, reflecting its pricing power and cost economics. The operating margin of 3.41 and net profit margin of 0.82 provide insight into operational efficiency.
| Gross Margin | 29.29 |
| Operating Margin | 3.41 |
| Pretax Margin | 2.08 |
| Profit Margin | 0.82 |
| EBITDA Margin | 3.41 |
GKB Ophthalmics Limited posts an Altman Z-Score of 1.80, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.80 |